ANAmit C. Nathwani

Amit C. Nathwani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amit C. Nathwani has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody

    by Vincent Muczynski, Olivier D. Christophe, Lewis Tanner, Charlotte Vayssiere, Alice Guérin, Caterina Casari, Jenny McIntosh, Doyoung Lee, Gavin Ling, Satyen Gohil, et al.

    The recent approval of adeno-associated virus (AAV)–based gene therapies for hemophilia A (HA) represents a major advancement in the management of this X-linked bleeding disorder, offering multiyear bleed protection and improved quality of life over factor VIII (FVIII) replacement. However, challenges remain, including concerns over long-term durability of expression and the difficulty of packaging the oversized FVIII transgene into AAV vectors. To address these limitations, we developed AAV8-Bi8, a liver-directed gene therapy encoding Bi8, a novel 54.5-kilodalton FVIII-mimetic antibody. Bi8 is expressed as a compact, single-chain tandem, single-chain fragment variable, and is delivered via a 4.4-kilobase expression cassette packaged within AAV8 capsids, well within the vector packaging capacity. In vitro, Bi8 demonstrated FVIII-mimetic activity, and effectively corrected FVIII-deficient human plasma to levels comparable with emicizumab, the current market standard. In vivo, a single administration of AAV8-Bi8 in FVIII-deficient mice resulted in dose-dependent, durable expression of Bi8, complete phenotypic correction of bleeding, and therapeutic equivalence to both emicizumab-treated and wild-type animals. Importantly, no toxicity or antidrug antibody responses were observed. This approach, based on delivering FVIII-mimetic antibodies through AAV rather than truncated FVIII transgenes, could provide a more flexible and efficient platform for gene therapy in HA. AAV8-Bi8 has the potential to offer sustained, lifelong hemostatic control, including in patients who have developed inhibitors to FVIII.


  • Open Access

    Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia

    by Kurtis Edwards, Kristina Zaitseva, Uzma Sayed, Emanuela V. Volpi, Amit Nathwani, John G. Gribben, Peter Lydyard, Sergey Krysov, Nino Porakishvili